63
Participants
Start Date
November 29, 2017
Primary Completion Date
November 9, 2021
Study Completion Date
December 17, 2021
ATIR101
ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
Cyclophosphamide
High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
T-cell depleted HSCT from a related, haploidentical donor
T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
T-cell replete HSCT from a related, haploidentical donor
T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
Institut Jules Bordet, Brussels
Universitair Ziekenhuis Antwerpen, Antwerp
Universitair Ziekenhuis Gasthuisberg, Leuven
Centre Hospitalier Universitaire de Liège, Liège
Algemeen Ziekenhuis Sint-Jan, Bruges
University Hospital Centre Zagreb, Zagreb
Weill Cornell Medical College, New York
Columbia University Medical Center, New York
Stony Brook University Hospital, Stony Brook
Milano Hospital, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan
Fondazione IRCCS Policlinico San Matteo, Pavia
Hospital Puerta de Hierro Majadahonda, Madrid
Emory University, Atlanta
UGC Hematología y Hemoterapia, Seville
Servicio de Hematología Hospital, Universitari I politècnic La Fe, Valencia
University Medical Center Mainz, Mainz
University of Kansas Cancer Center, Westwood
APHP Hospital Saint Louis, Paris
Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Munich
UCLA Center for Health Sciences, Los Angeles
City of Hope National Medical Center, Duarte
Hadassah Medical Center & Hadassah Hospital Ein Karem, Jerusalem
Stanford University School of Medicine, Stanford
Universitätsklinikum Würzburg, Würzburg
Oregon Health & Science University, Portland
Rambam Medical Center, Haifa
Chaim Sheba Medical Center, Tel Litwinsky
Sourasky Medical Center & Tel Aviv University, Tel Aviv
Moores UC San Diego Cancer Center, La Jolla
Massachusetts General Hospital, Boston
University of Michigan, Ann Arbor
Maisonneuve-Rosemont Hospital, Montreal
University Hospital Frankfurt, Goethe University, Frankfurt
Academisch Ziekenhuis Maastricht, Maastricht
Faculdade de Medicina da Universidade de Lisboa, Lisbon
University Hospital Barcelona Vall d' Hebron, Barcelona
Karolinska University Hospital, Stockholm
Heartlands Hospital, Birmingham
St James University Hospital, Leeds
Royal Liverpool University Hospital, Liverpool
Hammersmith Hospital, London
Manchester Royal Infirmary, Manchester
Lead Sponsor
Kiadis Pharma
INDUSTRY